A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT ID: NCT02151617
Last Updated: 2015-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2014-06-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
NCT03351751
Safety and Tolerability Study of Multiple Doses of PF-06305591
NCT01776619
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects
NCT01794364
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1-PF-06743649 or placebo
Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
PF-06743649
40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Placebo
Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Cohort 2-PF-06743649 or placebo
PF-06743649
To be decided dose, tablet once daily dosing for 14 days
Placebo
Placebo tablet once daily dosing for 14 days
Cohort 3-PF-06743649 or placebo
PF-06743649
To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Placebo
Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Cohort 4-PF-06743649 or placebo
PF-06743649
To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
Placebo
Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
Cohort 5-PF-06743649 or placebo
PF-06743649
Tablet, to be decided dose, once daily, 14 days
Placebo
Tablet, once daily, 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-06743649
40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Placebo
Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
PF-06743649
To be decided dose, tablet once daily dosing for 14 days
Placebo
Placebo tablet once daily dosing for 14 days
PF-06743649
To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Placebo
Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
PF-06743649
To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
Placebo
Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
PF-06743649
Tablet, to be decided dose, once daily, 14 days
Placebo
Tablet, once daily, 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion Criteria
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* Evidence of gout/hyperuricemia, measured sUA \>8 mg/dL at screening.
* Experienced an episode of nephrolithiasis or ureterolithiasis.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Haven Clinical Research Unit
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B7911001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.